Drug Discovery
  Molecular Analysis
  Organic and Organometallic Chemistry
  Medicinal Chemistry
  Synthetic Medicinal Chemistry and Chemical Biology
  Identification & validation of novel therapeutic targets - Biological evaluation of bioactive small molecules and drugs
  Structural Biology & Chemistry
  Molecular Endocrinology
  Signal Mediated Gene Expression
  Molecular & Cellular Ageing
  Biomedical Applications
  Holistic Approaches in Health
  Environment and Health
  Metabolic Engineering-Bioinformatics
  Biomarker Discovery & Translational Research
  Enzyme and Synthetic Biotechnology
  Biomimetics & Nanobiotechnology
  Conjugated Polymers for Healthcare, Bioelectronics and Bioimaging


Drug Discovery
Dr. Maria Koufaki | Research Director, Group Leader


Research interests are focused on the design and synthesis of bioactive heterocyclic molecules using two important strategies of Medicinal Chemistry: i) synthesis of hybrid molecules and ii) bioisosteric replacements.

In particular:

a) Chroman/hydroxytyrosol hybrids and bioisosteres as proteasome activators, against ageing and age related diseases.
b) Piperazinyl-purine analogues, possessing anti-inflammatory and/or antithrombotic activity, depending on piperazine substituents, acting as inhibitors of the NLRP3 inflammasome and/or specific kinases
c) New BRAFV600E inhibitors for the development of agents against colorectal cancer.

Research activities also involve the synthesis of heterocycles using microwave or ultrasound irradiation.

Ongoing Research Activities

Discovery of a new class of Bioinspired antiageing and neuroprotective proteasome activators


The 20S proteasome constitutes one of the vital cellular proteolytic machineries that maintain protein homeostasis (proteostasis) and participates in almost all cellular functions through the degradation of misfolded, redundant and damaged proteins.  The 20S proteasome consists of two α-rings which control the access to the proteolytic sites located in the two inner β-rings.
Proteasome has been reported to decline in terms of quantity and function during ageing and age-related diseases progression. Thus, proteasome activation constitutes a central mechanism for the deceleration of organismal aging and of the progression of neurodegenerative diseases such as Alzheimer's and Huntington's diseases, which are related with accumulation of toxic protein aggregates.

Although the research towards the development of small molecules as proteasome activators is scarce, the results so far suggest that activation of the proteasome complex constitutes a pioneer strategy for the deceleration of ageing and age-related diseases.
A novel class of hybrid compounds that combine structural features of the natural antioxidant vitamin E and of hydroxytyrosol connected through carefully selected linkers, was designed and synthesized by our group, leading to the development of an optimum structural proteasome activator (MK151) which improved healthspan markers in cellulo and in C. elegans model.
Based on these findings 16 novel hybrid compounds were designed and synthesized. Among them, 5 chroman analogues and 2 benzoxathiine (bioisostere of chroman ring) analogues were identified as structural activators of purified 20S proteasome complex. These compounds represent a new class of structural proteasome activators.

This class of compounds was further exploited by synthesizing more analogues. The biological results to date, from Dr. N. Chondrogianni’s group, show great promise with regards to the anti-ageing and neuroprotective effects of the new analogues in cellulo and in organismal level. Moreover, the most studied structural proteasome activator MK151 was synthesized on kg scale and incorporated in cosmetic preparations.

Supported by the following research grants: STHENOS-b 2017-2020 collaboration with members of other research teams of our Institute

logoRESET: “Bio-inspired antiaging proteasome activators” In collaboration with Intermed SA.


Design and synthesis of compounds targeting vascular inflammation

Inflammation is an important factor in promoting various diseases.  An increase of the proinflammatory cytokine interleukin-1β (IL-1β) levels has been associated to the pathogenesis inflammatory diseases such as cardiovascular disease (CVD) and cancer.
NLRP3 inflammasome, a multi-protein complex triggering the maturation of the proinflammatory cytokine IL-1β, has attracted tremendous research interest. NLRP3 assembly and IL-1β expression are promoted by extracellular ATP binding as a danger signal to purinergic P2X7 receptor. Currently no therapeutic agent able to hit different steps of inflammasome activation is available on the market. Thus, more than 30 novel compounds targeting P2X7R, were designed and synthesized in the context of D. Pournara’s PhD thesis and tested by Prof. Annette Nicke, Ludwig-Maximilians University in Munich, Germany
Supported by: Alexander S. Onassis Public Benefit Foundation fellowship.

NLRP3 activation has been linked to the pathophysiology of CVD. One of the major underlying factors for CVD is atherosclerosis, a multi-step chronic disease, characterized by a close interrelation between inflammation and thrombotic lesions that may lead to myocardial infarction. However, there is limited knowledge about targeting IL-1β against atherosclerosis, while current antithrombotic therapies are associated with a high bleeding risk.
In collaboration with Assoc. Prof. Karin H Franzén and Prof. Magnus Grenegård from Cardiovascular Research Centre (CVRC) at Örebro University (ÖU) Sweden, we revealed that two 6-piperazinyl-purine analogues synthesized by our group, inhibit the release of proinflammatory cytokines like IL-1 β and the expression of NLRP3 inflammasome genes and proteins, imparting an anti-inflammatory effect in aortic smooth muscle cells (AoSMCs).
Moreover, the involvement of kinases such as JAK and ROCK, in the pathogenesis of CVD could provide an exciting avenue for future research. Recent results of our fruitful collaboration with the CVRC, showed thatRho-associated protein kinase is the main molecular target for the anti-thrombotic activity of one 6-piperazinyl-purine analogue synthesized by our group.
Supported by: Swedish Knowledge foundation HÖG19 (KKS-HÖG19)

In the context of a recently approved Knowledge Foundation grant, Örebro University, seven Swedish biotech companies and three collaborating institutes will investigate the effects of new drug candidates against CVD and breast cancer. The novel drug candidates will be evaluated in cell and tissue models at Örebro University and the ICB/NHRF is a collaborating institute in the project and will contribute to the project with our expertise in chemical synthesis and in silico analysis, to learn more about the mechanisms of action of these drug candidates.
Supported by: Swedish Knowledge foundation Synergi21 (KKS-Synergi21)



Group Structure and Personnel

Dr Maria Koufaki, Research Director, Group Leader

Group members from 2018 to present

Dr Theano Fotopoulou (2018-)
Dr Sotirios Katsamakas (2019-)
Dr Michail Mamais (2019-2020)
Dr Georges Magoulas (2018)
Dr Alia Cristina Tenchiu (2018-2019)
Dimitra Pournara (PhD fellow 2015-2018)
Olga Kirkilesi MSc (2021)



The group collaborates with the other medicinal chemists of ICB and also with the groups of molecular analysis, molecular and cellular ageing, structural biology, signal mediated gene expression and biomarker discovery and translational research, through the participation in common grant applications and publications. 

International collaborations

  • Assoc. Prof. Karin H Franzén Cardiovascular Research Centre (CVRC), Örebro University, Sweden
    Prof. Magnus Grenegård, Cardiovascular Research Centre (CVRC), Örebro University, Sweden
  • Prof. Annette Nicke, Ludwig-Maximilians University in Munich, Germany
  • Dr. Marina Sokovic, Department of Plant Physiology, Institute for Biological Research “Siniša Stanković”, University of Belgrade, Serbia
  • Dr. Isabel C. F. R. Ferreira, Mountain Research Centre (CIMO, ESA), Polytechnic Institute of Braganca, Portugal
  • Dr. Simona Golic Grdadolnik, Department of Biomolecular Structure, National Institute of Chemistry, Ljubljana, Slovenia



  • Research, Create, Innovate MIS 5031214 (2018-2022) Project RESET: “Bio-inspired antiaging proteasome activators” Project Leader
  • Research Funding Program (2018-2021) BioImaging-GR “A Greek Research Infrastructure for Visualizing and Monitoring Fundamental Biological Processes”
  • Research Funding Program MIS 5002691 (2018-2021) OPENSCREEN-GR: “An open-access research infrastructure of target-based screening technologies and chemical biology for human and animal health, agriculture and the environment”
  • Research Funding Program KRIPIS2: (2017-2020) Project STHENOS-B: "Targeted therapeutic approaches against ageing and degenerative diseases, cancer in particular - Hit compounds optimization"
  • Research Funding Program KRIPIS: (2013-2015) Project STHENOS: "Targeted therapeutic approaches against ageing and degenerative diseases, cancer in particular”
  • REGPOT-2009-1/ARCADE 245866 (2010-2013) “Advancement of Research Capability for the Development of New Functional Compounds”  WP leader
  • Hellenic Society of Cardiology (2007-2010)Synthesis of nicorandil and adenosine derivatives as triggers of pharmacological preconditioning” (2010-2012)Development of agents mimicking postconditioning” 
  • EU Marie Curie Early Stage Training (EST) (2006-2010) “A European Research Training Site for the Design and Synthesis of Novel Neuroprotective and Hypoglycaemic Agents through a Multi-disciplinary approach”
  • E2050-4/2 Greek Ministry of Development (2006-2009)  “Design and Synthesis of Bioactive Molecules”
  • Northeastern Univ. Boston, Center for Drug Discovery (2006-2007) “Synthesis of tropolone derivatives” PI
  • Bilateral Collaboration of Greece–Hungary (2003-2006)“Synthesis of novel antiarrhythmics andstudy of their electrophysiological effects” PI
  • Operational Programme for Competitiveness, GSRT YB/39 (2004-2007) “Therapeutic Interventions Against Protozoan Infections”
  • GSRT programme Location and use of research results by the creation of new enterprises (Spin-off, 2003-2005) “New ether phospholipids as ultrasound contrast agents”
  • Univ. Connecticut PSA No 2328 (1998-1999) "Novel antiarrhythmics and anticancer ether lipids" PSA No 3324 (2001-2002) “Biologically active ether phospholipids” PSA No 3680 (2002-2003) "Novel Antioxidants" PSA No 4505 (2004-2005) "Novel Antioxidants and Bioactive ether phospholipids"
  • Excellence in the Research Institutes (2002-05) "Novel strategies against neurodegeneration"
  • PENED 99 181 (2000-2001) "Development of novel biochemical methods for the evaluation of compounds possessing antioxidant properties"




1988: PhD, University of Geneva, Faculty of Sciences, Switzerland.
Title: "Désoxyhydroxyaminosucres par cyclisation ou réduction des nitrones et radicaux libres correspondants. Nouvelles voies de synthèse d’oligosaccharides"

  • Pournara D.T., Durner A., Kritsi E., Papakostas A., Zoumpoulakis P., Nicke A., Koufaki M., Design, Synthesis, and in vitro Evaluation of P2X7 Antagonists. ChemMedChem 2020, 15, 2530–2543  
  • Kardeby, C., Paramel, G.V., Pournara, D., Fotopoulou, T., Sirsjö, A., Koufaki, M., Fransén, K., Grenegård, M., A novel purine analogue bearing nitrate ester prevents platelet activation by ROCK activity inhibition, Eur. J. Pharmacol. 2019, 857, 172428   
  • Smiljkovic M., Matsoukas M.-T., Kritsi E., Zelenko U., Golic Grdodolnik S., Calhelha R., Ferreira I., Sankovic-Babic S., Glamoclija J., Fotopoulou T., Koufaki M., Zoumpoulakis P., Sokovic M. Nitrate esters of heteroaromatic compounds as novel Candida albicans CYP51 enzyme inhibitors. ChemMedChem 2018, 13, 251-258
  • Pournara D., Heropoulos G.A. Koufaki M.* Convenient method for the synthesis of 5-(4-methoxyphenyl)-3H-1,2-dithiole-3-thione (ADT-OMe) and 5-(4-hydroxy phenyl)-3H-1,2-dithiol-3-thione (ADT-OH) using microwave irradiation. Tetrahedron Lett. 2017, 58, 2378-2380     
  • Fotopoulou T., Ćirić A., Kritsi E., Calhelha R.C., Ferreira I.C.F.R., Soković M., Zoumpoulakis P., Koufaki M.  Antimicrobial/Antibiofilm Activity and Cytotoxic Studies of β-Thujaplicin Derivatives. Archiv. Pharm. 2016, 698-709  
  • Koufaki M.*, Fotopoulou T., Kapetanou M., Heropoulos G.A., Gonos E.S., Chondrogianni N. Microwave-assisted synthesis of 3,5-disubstituted isoxazoles and evaluation of their anti-ageing activity. Eur. J. Med. Chem.2014, 83, 508-515    
  • Maugé L., Fotopoulou T., Delemasure S., Dutartre P., Koufaki M., Connat J.-L. In vitro inflammatory/anti-inflammatory effects of nitrate esters of purines. Eur. J. Pharmacol. 2014, 730, 148-156    
  • Koufaki M.*, Fotopoulou T., Heropoulos G.A. Synergistic effect of dual-frequency ultrasound irradiation in the one-pot synthesis of 3,5-disubstituted isoxazoles. Ultrason. Sonochem 2014, 21, 35-39     
  • Koufaki M.*, Fotopoulou T., Iliodromitis E. K., Bibli S. I., Zoga A., Kremastinos D.Th., Andeadou I.  Discovery of 6-[4-(6-nitroxyhexanoyl)piperazin-1-yl)]-9H-purine, as pharmacological post-conditioning agent. Bioorg. Med. Chem. 2012, 20, 5948-5956  
  • Koufaki M.*, Tsatsaroni A., Alexi X., Guerrand H., Zerva S., Alexis M.N. Isoxazole substituted chromans against oxidative stress-induced neuronal damage. Bioorg. Med. Chem. 2011, 19, 4841-4850    
  • Koufaki M.*, Theodorou E., Alexi X., Alexis M.N. Synthesis of a second generation chroman/catechol hybrids and evaluation of their activity in protecting neuronal cells from oxidative stress-induced cell death. Bioorg. Med. Chem. 2010, 18, 3898-3909    
  • Koufaki M.*, Theodorou E., Alexi X., Nikoloudaki F., Alexis M.N. Synthesis of tropolone derivatives and evaluation of their in vitro neuroprotective activity. Eur. J. Med. Chem.2010, 45, 1107-1112    
  • Koufaki M.*, Kiziridi C., Alexi X., Alexis M.N. Design and synthesis of novel neuroprotective 1,2-dithiolane/chroman hybrids.  Bioorg. Med. Chem., 2009, 17, 6432-6441  
  • Melagraki G., Afantitis A., Igglessi-Markopoulou O., Detsi A., Koufaki M., Kontogiorgis C., Hadjipavlou-Litina D.J. Synthesis and evaluation of the antioxidant and anti-inflammatory activity of novel coumarin-3-aminoamides and their alpha-lipoic acid adducts. Eur. J. Med. Chem. 2009, 44, 3020-3026     
  • Koini E.N., Papazafiri P., Vassilopoulos A., Koufaki M., Horváth Z., Koncz I., Virág L., Papp G.J., Varró A., Calogeropoulou T. 5,7,8-trimethyl-benzopyran and 5,7,8-trimethyl-1,4-benzoxazine aminoamide derivatives as novel antiarrhythmics against ischemia-reperfusion injury. J. Med. Chem. 2009, 52, 2328-2340     
  • Koufaki M.*, Detsi A.; Kiziridi C. Multifunctional lipoic acid conjugates. Curr. Med. Chem. 2009, 16, 4728-4742  
  • Andreadou I., Iliodromitis E.K., Farmakis D., Koufaki M., Tsotinis A., Kremastinos D.Th. Alternative pharmacological interventions that limit myocardial infarction Curr. Med. Chem. 200815, 3204-3213  
  • Andreadou I., Koufaki M., Iliodromitis E., Kremastinos D.Th. Pharmacological pre- and post-conditioning agents: reperfusion-injury of the heart revisited. Mini Rev. Med.Chem. 2008, 8, 952-959   
  • Fotopoulou T., Iliodromitis E. K., Koufaki M.*, Tsotinis A., Zoga A., Gizas V., Pyriochou A., Papapetropoulos A., Andreadou I., Kremastinos D.Th. Design and synthesis of nitrate esters of aromatic heterocyclic compounds as pharmacological preconditioning agents. Bioorg. Med. Chem. 2008, 16, 4523-4531    
  • Koufaki M.*, Kiziridi C., Nikoloudaki F., Alexis M.N. Design and synthesis of 1,2-dithiolane derivatives and evaluation of their neuroprotective activity. Bioorg. Med. Chem. Lett. 2007, 17, 4223-4227    
  • Kapou A., Avlonitis N., Detsi A., Koufaki M., Calogeropoulou T., Benetis N.P., Nikolaropoulos S., Mavromoustakos T. CoMFA and CoMSIA 3D Quantitative Structure-Activity Relationships of New Flexible Antileishmanial Ether Phospholipids. Bioorg. Med. Chem. 2007, 15, 1252-1265   
  • Detsi A, Bouloumbasi D., Prousis K.C., Koufaki M., Athanasellis G., Melagraki G., Afantitis A., Igglessi-Markopoulou O., Kontogiorgis C., Hadjipavlou-Litina D.J. Design and synthesis of novel quinolinone-3-aminoamides and their α-lipoic acid adducts as antioxidant and anti-inflammatory agents. J. Med. Chem. 2007, 50, 2450-2458    
  • Koufaki M.*, Kiziridi C., Papazafiri P., Vassilopoulos A., Varró A., Nagy Z., Farkas A., Makriyannis A. Synthesis and biological evaluation of benzopyran analogues bearing class III antiarrhythmic pharmacophores. Bioorg. Med. Chem. 2006, 14, 6666-6678     
  • Koufaki M.*, Theodorou E., Galaris D., Nousis L., Katsanou E. S, Alexis M.N. Chroman/catechol hybrids: Synthesis and evaluation of their activity against oxidative stress induced cellular damage. J. Med. Chem. 2006, 49, 300-306   
  • Papazafiri P., Avlonitis N., Angelou A., Calogeropoulou T., Koufaki M., Scoulica E., Fragiadaki I. Structure-activity relationships of antineoplastic ring-substituted ether phospholipid derivatives. Cancer Chemother. Pharmacol. 2005, 56, 261-270      
  • Koufaki M.*, Detsi A., Theodorou E., Kiziridi C., Calogeropoulou T., Vassilopoulos A., Kourounakis A., Rekka E., Kourounakis P., Gaitanaki C., Papazafiri P. Synthesis of Chroman Analogues of Lipoic Acid and Evaluation of their Activity against Reperfusion Arrhythmias. Bioorg. Med. Chem. 2004, 12, 4835-4841 
  • Calogeropoulou Τ., Detsi Α., Lekkas Ε, Koufaki Μ. Strategies in the design of prodrugs of anti HIV agents. Curr. Top. Med. Chem., 2003, 3, 1467-1495  
    Guest Editor Maria Koufaki.Title of the issue: "Therapeutic strategies against HIV infection"
  • Koufaki M.*, Calogeropoulou T., Rekka E., Chryselis M., Papazafiri P., Gaitanaki C., Makriyannis A. Bifunctional Agents for Reperfusion Arrhythmias.  Novel Hybrid Vitamin E/Class I Antiarrhythmics. Bioorg. Med. Chem. 2003, 11, 5209-5219 
  • Avlonitis N., Lekka E., Detsi A., Koufaki M., Calogeropoulou T., Skoulica E., Siapi E., Kyrikou I., Mavromoustakos T., Tsotinis A., Golic Grdadolnik S., Makriyannis A.  Antileishmanial Ring-Substituted Ether Phospholipids. J. Med. Chem. 2003, 46, 755-767
  • Detsi A.,Koufaki M., Calogeropoulou T. Synthesis of (Z)-4-hydroxytamoxifen and (Z)-2-(4-[1-(p-hydroxyphenyl)-2-phenyl]-1-butenyl)phenoxyacetic acid. J. Org. Chem. 2002, 67, 4608-4611   
  • Koufaki M.*, Calogeropoulou T., Detsi A., Roditis A., Kourounakis A., Papazafiri P., Tsiakitzis K., Gaitanaki C., Beis I., Kourounakis P. Novel potent inhibitors of lipid peroxidation with protective effects against reperfusion arrhythmias. J. Med. Chem. 2001, 44, 4300-4303   
  • Mavromoustakos T., Calogeropoulou T., Koufaki M., Kolocouris A., Demetzos K., Meng Z., Makriyannis A., Balzarini J., De Clercq E. Ether phospholipid-AZT conjugates possessing anti-HIV and anti-tumor cell activity. Synthesis, conformational analysis and study of their thermal effects on membrane bilayers.  J. Med. Chem.  2001, 44, 1702-1709    
  • Tronchet J.M.J., Koufaki M., Barbalat F., Geoffroy M. Blocked Sugar Analogues Bearing two or three N(sp3)-O Bonds. Carbohydr. Lett. 1999, 3, 255-262
  • Mavromoustakos T., Theodoropoulou E., Yang D.P., Lin S.Y., Koufaki M., Makriyannis A.  The conformational properties of the antineoplastic ether lipid 1- thiohexyl-2-O-methyl-S-glycero-3-phosphocholine. Chem. Phys. Lipids 1996, 84, 21-34    
  • Koufaki M., Polychroniou V., Calogeropoulou T., Tsotinis A., Drees M., Fiebig H.H., LeClerc S., Hendriks H.R., Makriyannis A. Alkyl and alkoxyethyl antineoplastic phospholipids. J. Med. Chem. 1996, 39, 2609-2614 
  • Koufaki M.*, Calogeropoulou T., Mavromoustakos T., Theodoropoulou E., Tsotinis. A., Makriyannis A. Synthesis of 2H-Labelled Alkoxyethyl Phosphodiester AZT Derivatives for Solid-State 2H-NMR Studies. J. Het. Chem. 1996, 33, 619-622  
  • Tsotinis A., Calogeropoulou T., Koufaki M., Souli Ch., Balzarini J., De Clercq E., Makriyannis A. Synthesis and Antiretroviral Evaluation of New Alkoxy and Aryloxy Phosphate Derivatives of AZT. J. Med. Chem. 1996, 39, 3418-3422
  • Calogeropoulou T., Koufaki M., Tsotinis A., Balzarini J., De Clercq E., Makriyannis A. Synthesis and anti-HIV evaluation of alkyl and alkoxyethyl phosphodiester AZT derivatives. Antiv. Chem. Chemother. 1995, 6, 43-49
  • Tronchet J.M.J., Koufaki M., Zosimo-Ladolfo G., Bernardinelli G. Spiro naphthoxazine derivatives of furanose sugars. J. Chem. Research 1992 (M) 2501, J. Chem. Research1992 (S) 293
  • Tronchet J.M.J., Koufaki M., Zosimo- Ladolfo G. Spacer arms bearing two N- hydroxyimino groups and nitroxyl free radicals thereof. Carbohydr. Res. 1991, 209,   299 
  • Tronchet J.M.J., Bizzozero N., Koufaki M., Habashi F., Geoffroy M. Analogs of blocked disaccharides bearing a N-hydroxyimino bridge and nitroxyl free radicals thereof. J. Chem. Research  1989 (M) 2601 J. Chem. Research 1989 (S334
Research monographs
Meeting abstracts
  • Vasilopoulou M.A., Fotopoulou T., Papaevgeniou N., Gioran A., Papahatjis D., Calogeropoulou T., Koufaki M., Chondrogianni N. A novel bioinspired proteasome activator against aging Free Radic. Biol. Med. 2021, 177, S122-S123
  • Papaevgeniou N., Fotopoulou T., Vasilopoulou M., Panat N., Pick E., Golan A., Gonos E.S., Papahatjis D., Calogeropoulou T., Koufaki M., Chondrogianni N. A novel bioinspired proteasome activator: potential anti-ageing strategies offered by mother nature (but not only). Free Radic Biol Med. 2019, 139, S78-S79
  • Andeadou I., Bibli S.I., Zhou Z., Fotopoulou T., Koufaki M., Anastasiou-Nana M.,  Papapetropoulos A., Iliodromitis E.K. Pharmacological characterization and elucidation of the molecular mechanism of action of a novel purine analogue which has superior effects to ischemic postconditioning. Eur. Heart J. 2014, 35S1, 386-387 
  • Andeadou I., Fotopoulou T., Georgakopoulos A., Zoga A., Koufaki M., Kremastinos D.Th., Iliodromitis E.K., Anastasiou-Nana M. Nitric oxide donors as pharmacological postconditioning agents: the formation of peroxynitrite during reperfusion plays a critical role. Eur. Heart J. 2011, 32S1, 331-332
  • Andreadou I., Fotopoulou T., Koufaki M., Tsotinis A., Zoga A., Pyriochou A., Farmakis D., Iliodromitis E.K., Kremastinos D.Th. Novel pharmacological compounds as triggers of preconditioning in vivo. J. Am. Coll. Cardiol. 2008, 51, Suppl. A, A183
  • Andreadou I., Fotopoulou T., Koufaki M., Tsotinis A., Zoga A., Papapetropoulos A., Iliodromitis E.K., Kremastinos, D.Th.  Development of novel pharmacological agents that precondition the ischemic heart in vivo through parallel and combined molecular mechanisms Eur. Heart J. 2008, 29, Suppl. 1, 110-111
  • Andreadou I., Fotopoulou T., Koufaki M., Tsotinis A., Zoga A., Gizas V., Iliodromitis E., Kremastinos D.Th. Novel pharmacological compounds as triggers of ischemic preconditioning in vivo. J. Mol. Cell. Cardiol. 2007, 42, S1, S178
Chapter in book

Maria Koufaki and Anastasia Detsi.  Design and Synthesis of Antioxidant α-Lipoic Acid Hybrids. Advanced Protocols for Oxidative Stress II Series: Methods in Molecular Biology, Vol. 594, Armstrong, Donald (Ed.) 2010, p. 297-309 DOI 10.1007/978-1-60761-411-1_21

  • GR 20180100094, WO2019171088A1 Applicant: NHRF, EP3761950A1, Applicant: Ioulia and Irene Tseti Pharmaceutical Laboratories SA. Inventors: Koufaki M., Calogeropoulou T., Chondrogianni N., Papahatjis D., Gonos E.S., Fotopoulou T., Proussis K., Chazapi E. “Bio-inspired proteasome activators with anti-ageing activity”
  • GR20050100100. Calogeropoulou T., Koufaki M. “Ultrasound contrast agents containing anticancer ether phospholipids”
  • US2003/34225, WO2004041167, CN1742017, CA2503058, AU2003285071, EP1578754, US2006105998 Calogeropoulou T., Koufaki M., Avlonitis N., Makriyannis A."Antiprotozoal ring-substituted phospholipids"
  • WO0204438, US2004259763, CA2415523, EP1301504, DE60106922T, ΕS231514Τ Applicant: UNI-PHARMA SA Inventors: Koufaki M., Calogeropoulou T., Makriyannis A. "Bifunctional agents possessing antioxidant and antiarrhythmic activity"







© National Hellenic Research Foundation (NHRF), 48 Vassileos Constantinou Ave., 11635 Athens, Greece, Tel. +302107273700, Fax. +302107246618